Cellectricon and AstraZeneca Partners in new High Throughput Ion Channel Drug Discovery Technology
News Jun 12, 2008
Cellectricon has announced a new collaborative agreement with AstraZeneca. Under the agreement Cellectricon will provide AstraZeneca with two of its new high throughput platform, Dynaflow® HT, for ion channel screening.
Cellectricon and AstraZeneca formed and announced collaboration in May 2006 aiming to find a solution to major bottlenecks in ligand gated ion channel screening.
According to both companies, the results from this collaboration have successfully demonstrated the performance of Cellectricon's cell-based microfluidic screening platform. It has clearly demonstrated the opportunity to introduce the fully automated Dynaflow®HT System with unmatched level of stability and throughput while still delivering unique measurement data quality. The Dynaflow®HT System will be launched and commercially available in 2009.
"Collaborating with AstraZeneca has been most rewarding," says Jonas Ohlsson, CEO at Cellectricon. "Driven by solving bottlenecks in drug discovery, Cellectricon's strategy is to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations."
"This collaboration aims to accelerate our efforts in ion channel drug discovery and has been very fruitful to date. We look forward to working with the Dynaflow®HT Systems and see the impact of their throughput and cost effectiveness," says Dr. Jan-Erik Nystrom, VP Local Discovery Research Area CNS & Pain Control, Sodertalje, Sweden.
"The strength of this platform is that it is based on many years of cutting-edge academic and industrial research in ion channel drug discovery. I am happy to see us taking a new step together with a leading partner in advancing it further," says Dr. Jon Sinclair, VP Research & Development at Cellectricon.
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE